For over twenty years, the Food and Drug Law Institute (FDLI) has presented the Distinguished Service and Leadership Award to individuals for their sustained service and leadership or exceptional contribution to the food and drug law community. PPMD President Pat Furlong joins a very distinguished group of advocacy leaders and we couldn’t be more proud or grateful to her for her ongoing leadership in the Duchenne and rare disease community.
The FDLI award event last night was an amazing milestone for FDLI -- and more, for us. Pat's groundbreaking leadership was recognized beautifully and her remarks left no question in the minds of those gathered as to why she was selected.
Pat opened her comments reflecting that by the time her boys were 16 they could no longer raise their arms -- to care for themselves, to eat, to hug their mom. She concluded her remarks by "asking everyone gathered to raise their glasses in honor of all of the 16 year olds with Duchenne who cannot -- but thanks to the engagement with partners like those gathered in the room tonight and the 28 companies now in our Duchenne space -- may someday have real therapeutic options."
Food and Drug Law Institute Announces
Distinguished Service and Leadership Award Winners
The Food and Drug Law Institute (FDLI) will present its Distinguished Service and Leadership Awards on Wednesday, December 9, 2015. The awards ceremony will be held at the Urbana Restaurant in Washington, DC from 6:00 - 7:30 pm. Four leaders in the food and drug law community will be recognized for their notable service and leadership:
Pat Furlong is Founding President and CEO, Parent Project Muscular Dystrophy, the largest nonprofit organization in the United States solely focused on Duchenne muscular dystrophy.
David J. Horowitz is Deputy General Counsel at the Department of Health and Human Services (HHS), overseeing legal services provided to FDA, CDC, and NIH, as well as international and emergency preparedness legal issues for the Department.
Philip Katz is a Partner in the law firm of Hogan Lovells in Washington, DC, and Practice Area Leader of the firm's pharmaceutical and biotechnology practice group.
Karen Midthun is the Director of the Center for Biologics Evaluation and Research (CBER) at FDA. CBER regulates vaccines, blood and blood products, and cellular, tissue, and gene therapies. Her responsibilities include oversight of the investigational phases of product development, decisions regarding licensure, and post-licensure surveillance activities.
FDLI, founded in 1949, is a non-profit organization that provides a marketplace for discussing food and drug law issues through conferences, publications and member interaction. FDLI’s scope includes food, drugs, animal drugs, biologics, cosmetics, diagnostics, dietary supplements, medical devices and tobacco.